NDT Advance Access originally published online on July 27, 2007
Nephrology Dialysis Transplantation 2007 22(10):3052-3054; doi:10.1093/ndt/gfm490
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Epoetin delta in the management of renal anaemia: results of a 6-month study
Division of Nephrology, Saint Louis University, St Louis, MO, USA
Correspondence to: Kevin J. Martin, MB, B.Ch, FACP, Division of Nephrology, Saint Louis University, 3634 Vista Avenue, St Louis, MO 63110, USA. Email: martinkj{at}slu.edu
 |
Abstract |
|---|
Background. Epoetin delta is an epoetin that, unlike existing agents, is produced in a human cell line. The present study investigated the efficacy and tolerability of intravenous (i.v.) epoetin delta compared with i.v. epoetin alfa.
Methods. This was a 6-month, multicentre, randomized, double-blind trial in haemodialysis patients previously receiving epoetin alfa. Haematological parameters were assessed, and adverse events monitored. Equivalent efficacy was defined as a difference in mean haemoglobin between the two agents over weeks 12–24 of 
1 g/dl with a 90% confidence interval (CI) within the range –1 to 1 g/dl.
Results. In total, 560 patients received epoetin delta while 192 received epoetin alfa, and 76.8% and 79.7% of patients, respectively, completed the study. Both agents showed similar efficacy in controlling anaemia: the point estimate for the difference in mean haemoglobin over weeks 12–24 was 0.01 g/dl (90% CI, –0.13, 0.15 g/dl), confirming equivalence. Adverse events were those expected in dialysis patients. Events possibly related to treatment occurred in 9.2% of patients receiving epoetin delta and 8.4% receiving epoetin alfa. Serious adverse events (SAEs) occurred in 33.0% and 26.7% of patients in the epoetin delta and epoetin alfa groups, respectively. Six patients in the epoetin delta group experienced an SAE considered possibly related to treatment (mostly access-related clotting), compared with no patient in the epoetin delta group. None of these SAEs were life threatening.
Conclusions. Epoetin delta was shown to have an equivalent efficacy and safety profile to epoetin alfa in this 6-month study.
Keywords: Clinical trial; epoetin delta; haemodialysis; randomized controlled trial; renal anaemia
Received for publication: 22. 8.06
Accepted in revised form: 27. 6.07
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. S. Spinowitz Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin {delta} Haematologica, May 1, 2008; 93(5): 761 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Macdougall Novel Erythropoiesis-Stimulating Agents: A New Era in Anemia Management Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 200 - 207. [Abstract] [Full Text] [PDF]
|
|